We are a team of scientists and physicians committed to changing the world.


About Us


Brooklyn ImmunoTherapeutics (BTX) is a clinical-stage biopharmaceutical company committed to creating a world where patients and families with high unmet medical needs have access to effective treatments.

We are pioneers in using the latest technologies such as synthetic mRNA, cellular reprogramming, gene editing, and complex human-derived mixed cytokines. These advances fuel our ongoing programs, including iPSC-derived MSC (iMSC), gene-edited iMSC, and in vivo gene editing. Additionally, we have developed the IRX-2 immuno-therapy, which is approaching the conclusion of its Phase 2B study.

The BTX team is diverse in its backgrounds and experience and federated around the use of science and technology to advance transformative therapies to meet the needs of patients.


Board of Directors


Charles Cherington

Chairman

READ BIO

Howard J. Federoff, MD, PhD

CEO

READ BIO

Luba Greenwood

Erich Mohr, Ph.D.

Dennis Langer, M.D., J.D.

READ BIO

Executive Team


Howard J. Federoff, MD, PhD

CEO

READ BIO

Jay Sial

Chief Administrative Officer

READ BIO

Kevin D’Amour

Chief Scientific Officer

READ BIO

Lynn Sadowski-Mason, MS

EVP Clinical Operations

READ BIO

Ron Guido, MS, MS Pharm. Med.

Chief Development Officer

READ BIO

Roger Sidhu

Chief Medical Officer

READ BIO

Sandra Gurrola

Vice President, Finance

READ BIO

Susan McClatchey

Vice President, Head of Quality

READ BIO

Scientific Advisory Board


Gregory Wolf, MD

Matthew During, MD, PhD

Michael Andreeff, MD, PhD

READ BIO

Christopher Rohde

READ BIO

Culture


Brooklyn ImmunoTherapeutics is a small and diverse team of people who share a vision: To create a world where patients and families with high unmet medical needs have access to effective treatments. While these objectives are inspiring and require an enormous commitment of ability and energy, we cultivate a collegial atmosphere of collaboration engagement. Despite our varied backgrounds, we all share an inherent curiosity, applying it to the work we do and creating a spirit of beneficence that characterizes our culture. We take our shared vision of changing the world seriously, but we do so in a way that creates a nurturing environment that makes our lives better at the same time.

Mission

We boldly develop novel therapeutics utilizing mRNA-based cell engineering and complex cytokines.

Vision

To create a world where patients and families with high unmet medical needs have access to effective treatments.

Values

Beneficent

We operate authentically, sharing our actions and intentions.

Scientific

We adopt the most robust approach, including fundamental, translational, and real-world evidence.

Curious

We are committed to excellence and challenging assumptions.

Collaborative

We apply multi-disciplinary approaches.

Inclusive

We foster an environment that ensures diversity and equity while focusing on the communities we serve.

Engaging

We involve patients and providers, collaborate with regulators, and empower our employees.

Relentless

We persistently drive toward new learning and innovation.